Tsuyoshi Goto Selected Research

Fibrosis (Cirrhosis)

1/2021	Biallelic variants in LIG3 cause a novel mitochondrial neurogastrointestinal encephalomyopathy.
1/2020	Anti-Inflammatory and Antioxidative Properties of Isoflavones Provide Renal Protective Effects Distinct from Those of Dietary Soy Proteins against Diabetic Nephropathy.
1/2017	Dietary low-fat soy milk powder retards diabetic nephropathy progression via inhibition of renal fibrosis and renal inflammation.
1/2015	Quercetin reduces obesity-induced hepatosteatosis by enhancing mitochondrial oxidative metabolism via heme oxygenase-1.
2/2014	Involvement of mast cells in adipose tissue fibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tsuyoshi Goto Research Topics

Disease

46	Obesity 03/2024 - 01/2008
25	Inflammation (Inflammations) 03/2024 - 08/2003
22	Insulin Resistance 12/2022 - 09/2007
12	Hyperlipidemias (Hyperlipidemia) 12/2023 - 03/2002
12	Thrombosis (Thrombus) 10/2019 - 01/2011
11	Body Weight (Weight, Body) 05/2023 - 02/2010
9	Cardiovascular Diseases (Cardiovascular Disease) 12/2017 - 03/2002
8	Myocardial Infarction 04/2022 - 11/2013
5	Hyperglycemia 03/2023 - 12/2011
5	Death (Near-Death Experience) 03/2021 - 01/2014
5	Fibrosis (Cirrhosis) 01/2021 - 02/2014
4	Type 2 Diabetes Mellitus (MODY) 05/2023 - 01/2010
4	Aortic Valve Stenosis (Aortic Stenosis) 01/2021 - 01/2014
4	Hemorrhage 01/2020 - 01/2017
4	Osteonecrosis (Kienbock's Disease) 09/2019 - 02/2010
4	Pathologic Constriction (Stenosis) 01/2018 - 07/2015
4	Atherosclerosis 03/2016 - 08/2003
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2014 - 01/2008
3	Glucose Intolerance 11/2022 - 04/2010
3	Acute Coronary Syndrome 01/2018 - 01/2013
3	Dyslipidemias (Dyslipidemia) 03/2016 - 01/2011
3	Hyperinsulinism (Hyperinsulinemia) 12/2012 - 03/2012
2	Diabetes Complications 11/2022 - 12/2021
2	ST Elevation Myocardial Infarction 03/2021 - 12/2017
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 01/2015
2	Neoplasms (Cancer) 07/2020 - 01/2010
2	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020 - 01/2017
2	Non-alcoholic Fatty Liver Disease 04/2019 - 01/2018
2	Wounds and Injuries (Trauma) 01/2019 - 05/2018
2	Metabolic Diseases (Metabolic Disease) 01/2018 - 11/2011
2	Hypercholesterolemia 01/2014 - 04/2011
1	Disease Progression 05/2023

Drug/Important Bio-Agent (IBA)

17	LipidsIBA 03/2024 - 01/2010
15	Glucose (Dextrose)FDA LinkGeneric 12/2022 - 09/2009
13	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 04/2019 - 12/2009
11	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 04/2010
9	Insulin (Novolin)FDA Link 11/2017 - 09/2009
6	LigandsIBA 12/2023 - 05/2008
6	CytokinesIBA 10/2017 - 01/2012
5	Messenger RNA (mRNA)IBA 03/2024 - 12/2009
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2003
5	AdiponectinIBA 01/2022 - 01/2008
5	Sirolimus (Rapamycin)FDA Link 01/2018 - 05/2011
5	PhytochemicalsIBA 11/2016 - 05/2008
4	AdipokinesIBA 01/2022 - 01/2008
4	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 04/2019 - 01/2008
4	omega-Chloroacetophenone (Mace)IBA 09/2017 - 02/2011
4	Triglycerides (Triacylglycerol)IBA 03/2016 - 12/2011
3	LDL CholesterolIBA 03/2021 - 04/2011
3	Soybean Proteins (Soy Protein)IBA 01/2020 - 08/2013
3	Uncoupling Protein 1IBA 04/2019 - 10/2017
3	HDL LipoproteinsIBA 04/2019 - 04/2011
3	SteroidsIBA 01/2018 - 02/2010
3	MetalsIBA 01/2018 - 01/2013
3	QuercetinIBA 06/2017 - 01/2014
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 08/2003
3	BezafibrateIBA 09/2013 - 05/2011
2	Conditioned Culture MediaIBA 03/2024 - 07/2013
2	Blood Glucose (Blood Sugar)IBA 05/2023 - 01/2016
2	CanagliflozinIBA 05/2023 - 01/2020
2	3- (4- (4- (3- methyl- 1- phenyl- 1H- pyrazol- 5- yl)piperazin- 1- yl)pyrrolidin- 2- ylcarbonyl)thiazolidineIBA 05/2023 - 11/2018
2	Dipeptidyl-Peptidase IV InhibitorsIBA 05/2023 - 11/2018
2	Sodium-Glucose Transporter 2 InhibitorsIBA 05/2023 - 01/2020
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2023 - 03/2021
2	Pyruvaldehyde (Methylglyoxal)IBA 11/2022 - 12/2021
2	Peptides (Polypeptides)IBA 01/2022 - 01/2014
2	Everolimus FDA Link 01/2020 - 10/2019
2	Heme Oxygenase-1IBA 09/2019 - 01/2015
2	Carrier Proteins (Binding Protein)IBA 04/2019 - 01/2014
2	CarbohydratesIBA 04/2019 - 12/2012
2	Peroxisome ProliferatorsIBA 04/2019 - 01/2015
2	Branched-Chain Amino AcidsIBA 01/2019 - 11/2017
2	Nonesterified Fatty Acids (NEFA)IBA 11/2017 - 01/2017
2	FlavonoidsIBA 06/2017 - 07/2012
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2017 - 01/2015
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2017 - 01/2013
2	LDL Lipoproteins (beta Lipoproteins)IBA 03/2016 - 04/2011
2	HDL CholesterolIBA 03/2016 - 04/2011
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2015 - 04/2011
2	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2014 - 02/2010
2	auraptenIBA 07/2013 - 12/2011
2	bixinIBA 12/2012 - 12/2009
2	tilirosideIBA 07/2012 - 03/2012
2	DiosgeninIBA 01/2011 - 11/2010
2	PPAR gammaIBA 12/2009 - 08/2003
2	dehydroabietic acidIBA 09/2009 - 05/2008
2	Monocyte Chemoattractant ProteinsIBA 01/2008 - 09/2007
1	AcetoneIBA 03/2024
1	Nitric Oxide Synthase (NO Synthase)IBA 12/2023
1	Transcription Factors (Transcription Factor)IBA 12/2023
1	PPAR alphaIBA 12/2023
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2023
1	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 12/2022
1	ElementsIBA 12/2022

Therapy/Procedure

19	Stents 01/2020 - 01/2011
8	Therapeutics 05/2023 - 09/2010
6	Percutaneous Coronary Intervention 04/2022 - 01/2014
5	Transcatheter Aortic Valve Replacement 01/2021 - 01/2014
4	Oral Administration 01/2020 - 04/2011
4	Drug-Eluting Stents 01/2018 - 05/2011